Allergan’s Manufacturing Challenges Produce Second Levadex “Complete Response” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA again cites inspection issues related to a third-party facility where the product canister for the migraine drug is manufactured, as well as the manufacturing process itself; Allergan says it recently completed an acquisition of that third-party firm, thereby bringing the inhaled treatment’s manufacturing in-house.
You may also be interested in...
Allergan Manufacturing Headaches Continue For Semprana
Inhalable acute migraine drug previously known as Levadex receives third “complete response” letter from FDA.
Allergan Manufacturing Headaches Continue For Semprana
Inhalable acute migraine drug previously known as Levadex receives third “complete response” letter from FDA.
With Or Without Generic Competition, Allergan’s CEO Sees Growth Ahead
Prospects for its key ophthalmic drug Restasis are still up in the air, despite recent positive news, but Allergan CEO expects double-digit sales and earnings growth for the next five years, driven by operating efficiencies and creation of new markets.